Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 4, 2005, Pages 358-360

  Pappas, Periklis ^a   Karavasilis, Vasilis ^b   Briasoulis, Evangelos ^b   Pavlidis, Nicholas ^b   Marselos, Marios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

CGP74588; End stage renal disease; Hemodialysis; Imatinib; Pharmacokinetics; Renal function

Indexed keywords

CGP 74588; DRUG METABOLITE; IMATINIB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CASE REPORT; CONTROLLED STUDY; DIALYSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; LIVER METASTASIS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER NEOPLASMS; PIPERAZINES; PYRIMIDINES; RENAL DIALYSIS;

EID: 23244433963     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1031-2     Document Type: Article

References (12)

1. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502
2. Nikolova Z, Peng B, Hubert M, Sieberling M, Keller U, Ho YY et al (2004) Bioequivalence, safety, and tolerability of i-matinib tablets compared with capsules. Cancer Chemother Pharmacol 53:433-438
3. Croom KF, Perry CM (2003) Imatinib mesylate: in the treatment of gastrointestinal stromal tumors. Drugs 63:513-522
4. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935-942
5. Bauer S, Hagen V, Pielken HJ, Bojko P, Seeber S, Schutte J (2002) Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 13:847-849
6. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102-106
7. Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313-323
8. Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS et al (2002) US food and drug administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 7:393-400
9. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R et al (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294
10. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942
11. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
12. Gambacorti-Passerini C, le CP, Mologni L, Fanelli M, Bertazzoli C, Marchesi E et al (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394